Srdan Verstovsek, MD, PhD

Articles

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13th 2020

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22nd 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31st 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

November 26th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.

Dr. Verstovsek on Accelerated Phase Myelofibrosis

October 10th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses accelerated phase myelofibrosis.

x